In the field of oncology, the Signaling Lymphocyte Activation Molecule (SLAM) family is emerging as pivotal in modulating immune responses within tumor environments. The SLAM family comprises nine receptors, mainly found on immune cell surfaces. These receptors play complex roles in the interaction between cancer and the host immune system. Research suggests SLAM’s role in both enhancing and dampening tumor-immune responses, influencing the progression and treatment outcomes of various cancers. As immunotherapy advances, resistance remains an issue. The nuanced roles of the SLAM family might provide answers. With the rise in technologies like single-cell RNA sequencing and advanced imaging, there is potential for precise SLAM-targeted treatments. This review stresses patient safety, the importance of thorough clinical trials, and the potential of SLAM-focused therapies to transform cancer care. In summary, SLAM’s role in oncology signals a new direction for more tailored and adaptable cancer treatments.
在肿瘤学领域，信号淋巴细胞激活分子（SLAM）家族正逐渐成为调控肿瘤微环境中免疫反应的关键因素。该家族包含九种主要表达于免疫细胞表面的受体，在肿瘤与宿主免疫系统的相互作用中扮演着复杂角色。研究表明，SLAM家族既能增强也能抑制肿瘤免疫应答，从而影响多种癌症的进展及治疗效果。随着免疫疗法的进步，耐药性问题依然存在，而SLAM家族的多重调控功能可能为此提供解决思路。单细胞RNA测序和先进成像等技术的发展，为开发精准靶向SLAM的治疗策略创造了条件。本综述强调患者安全性、严谨临床试验的重要性，以及聚焦SLAM的疗法变革癌症治疗的潜力。总体而言，SLAM在肿瘤学中的作用标志着癌症治疗向更精准、适应性更强的新方向迈进。
SLAM Modification as an Immune-Modulatory Therapeutic Approach in Cancer
肿瘤(癌症)患者之家